title: Influence of noradrenaline on progesterone synthesis and post-translational processing of oxytocin synthesis in the bovine corpus luteum.
abstract: Noradrenaline (NA) influences secretory function of the bovine corpus luteum (CL), stimulating secretion of progesterone and ovarian oxytocin (OT). To study whether NA is able to stimulate progesterone synthesis and to affect post-translational OT processing, different doses of NA alone or in combination with different doses of OT were added to bovine CL slices from 8 to 13 d of the estrous cycle. To determine which receptors NA affects, and if dopamine (DA) also affects CL function, we used NA or DA combined with a beta-antagonist (propranolol). The results indicated that NA stimulates both luteal progesterone and OT content; furthermore, it increased the activity of 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) and peptidyl glycine-alpha-amidating mono-oxygenase (PGA), terminal enzymes in synthesis of these 2 hormones. The stimulating effect of NA was inhibited by propranolol and by pre-treatment of CL slices with high OT doses. Post-translational processing of OT synthesis by PGA activation was also stimulated by DA, but this effect was inhibited by beta-receptor blocker. Thus DA acts in CL as a NA precursor. In conclusion, it can be assumed that the noradrenergic system affects CL secretory function on different levels of regulation. Furthermore, a high concentration of OT in CL prevents NA from activating PGA and thus decreases post-translational OT synthesis.
authors.affiliation: Institute of Animal Reproduction and Food Research of Polish Academy of Sciences, Olsztyn-Kortowo, Poland.
authors.forename: M
authors.initials: M
authors.lastname: Bogacki
authors.forename: J
authors.initials: J
authors.lastname: Kotwica
mesh_terms: D015096:3-Hydroxysteroid Dehydrogenases / Q000378:metabolism; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D002417:Cattle / Q000378:metabolism*; D003338:Corpus Luteum / Q000187:drug effects / Q000378:metabolism*; D004298:Dopamine / Q000494:pharmacology; D005260:Female; D006899:Mixed Function Oxygenases / Q000378:metabolism; D009097:Multienzyme Complexes; D009638:Norepinephrine / Q000494:pharmacology*; D010121:Oxytocin / Q000096:biosynthesis*; D011374:Progesterone / Q000096:biosynthesis*; D011433:Propranolol / Q000494:pharmacology; D011499:Protein Processing, Post-Translational / Q000187:drug effects*
chemical_list: D000319:Adrenergic beta-Antagonists; D009097:Multienzyme Complexes; D011374:Progesterone; D010121:Oxytocin; D011433:Propranolol; D006899:Mixed Function Oxygenases; D015096:3-Hydroxysteroid Dehydrogenases; C035189:peptidylglycine monooxygenase; D004298:Dopamine; D009638:Norepinephrine